Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Tanja D de Gruijl"'
Autor:
Rieneke van de Ven, Tiffany C. Blair, Rom Leidner, Marka R. Crittenden, Tanja D. de Gruijl, David J. Friedman, Shelly Bambina, Yaping Wu, Michael J. Gough, Jason R. Baird, Terry R. Medler, Zhaoyu Sun, Gwen Kramer, R. Bryan Bell, Victoria Troesch
Publikováno v:
Baird, J R, Bryan Bell, R, Troesch, V, Friedman, D, Bambina, S, Kramer, G, Blair, T C, Medler, T, Wu, Y, Sun, Z, de Gruijl, T D, van de Ven, R, Leidner, R S, Crittenden, M R & Gough, M J 2018, ' Evaluation of explant responses to STING ligands: Personalized immunosurgical therapy for head and neck squamous cell carcinoma ', Cancer Research, vol. 78, no. 21, pp. 6308-6319 . https://doi.org/10.1158/0008-5472.CAN-18-1652
Cancer Research, 78(21), 6308-6319. American Association for Cancer Research Inc.
Cancer Research, 78(21), 6308-6319. American Association for Cancer Research Inc.
Surgeons have unique in situ access to tumors enabling them to apply immunotherapies to resection margins as a means to prevent local recurrence. Here, we developed a surgical approach to deliver stimulator of interferon genes (STING) ligands to the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7508ffb1e749659e9c47c89c72a5fdb
https://research.vumc.nl/en/publications/63a98368-5257-4df4-94f3-ee309ecc134c
https://research.vumc.nl/en/publications/63a98368-5257-4df4-94f3-ee309ecc134c
Autor:
Kamran Nazmi, Tanja D. de Gruijl, Gert Storm, Medha D. Joshi, Erik Hooijberg, Jan G. M. Bolscher, Yvette van Kooyk, Martino Ambrosini, Wendy W. J. Unger, Sven C. M. Bruijns, Hakan Kalay, Astrid J. van Beelen, Marleen I. Verstege, Louis van Bloois, Cynthia M. Fehres
Publikováno v:
Journal of Controlled Release, 160(1), 88-95. Elsevier
Unger, W W J, van Beelen, A J, Bruijns, S C M, Joshi, M, Fehres, C M, van Bloois, L, Verstege, M I, Ambrosini, M, Kalay, H, Nazmi, K, Bolscher, J G, Hooijberg, E, de Gruijl, T D, Storm, G & van Kooyk, Y 2012, ' Glycan-modified liposomes boost CD4(+) and CD8(+) T-cell responses by targeting DC-SIGN on dendritic cells ', Journal of Controlled Release, vol. 160, no. 1, pp. 88-95 . https://doi.org/10.1016/j.jconrel.2012.02.007
Unger, W W J, van Beelen, A J, Bruijns, S C, Joshi, M, Fehres, C M, van Bloois, L, Verstege, M I, Ambrosini, M, Kalay, H, Nazmi, K, Bolscher, J G, Hooiberg, E, de Gruijl, T D, Storm, G & van Kooyk, Y 2012, ' Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells ', Journal of Controlled Release, vol. 160, no. 1, pp. 88-95 . https://doi.org/10.1016/j.jconrel.2012.02.007
Unger, W W J, van Beelen, A J, Bruijns, S C M, Joshi, M, Fehres, C M, van Bloois, L, Verstege, M I, Ambrosini, M, Kalay, H, Nazmi, K, Bolscher, J G, Hooijberg, E, de Gruijl, T D, Storm, G & van Kooyk, Y 2012, ' Glycan-modified liposomes boost CD4(+) and CD8(+) T-cell responses by targeting DC-SIGN on dendritic cells ', Journal of Controlled Release, vol. 160, no. 1, pp. 88-95 . https://doi.org/10.1016/j.jconrel.2012.02.007
Unger, W W J, van Beelen, A J, Bruijns, S C, Joshi, M, Fehres, C M, van Bloois, L, Verstege, M I, Ambrosini, M, Kalay, H, Nazmi, K, Bolscher, J G, Hooiberg, E, de Gruijl, T D, Storm, G & van Kooyk, Y 2012, ' Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells ', Journal of Controlled Release, vol. 160, no. 1, pp. 88-95 . https://doi.org/10.1016/j.jconrel.2012.02.007
Cancer immunotherapy requires potent tumor-specific CD8(+) and CD4(+) T-cell responses, initiated by dendritic cells (DCs). Tumor antigens can be specifically targeted to DCs in vivo by exploiting their expression of C-type lectin receptors (CLR), wh
Autor:
Sjoerd H. van der Burg, Suzanne van Duikeren, Tanja D. de Gruijl, Angelino T. Tromp, Jaap Oostendorp, Ana Luisa Silva, Rodney A. Rosalia, Clemens W.G.M. Löwik, Ferry Ossendorp, Wim Jiskoot, Luis J. Cruz
Publikováno v:
Biomaterials, 40, 88-97. Elsevier BV
Biomaterials, 40, 88-97
Rosalia, R A, Cruz, L J, van Duikeren, S, Tromp, A T, Silva, A L, Jiskoot, W, de Gruijl, T D, Lowik, C, Oostendorp, J, van der Burg, S H & Ossendorp, F 2015, ' CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses ', Biomaterials, vol. 40, pp. 88-97 . https://doi.org/10.1016/j.biomaterials.2014.10.053
Biomaterials, 40, 88-97
Rosalia, R A, Cruz, L J, van Duikeren, S, Tromp, A T, Silva, A L, Jiskoot, W, de Gruijl, T D, Lowik, C, Oostendorp, J, van der Burg, S H & Ossendorp, F 2015, ' CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses ', Biomaterials, vol. 40, pp. 88-97 . https://doi.org/10.1016/j.biomaterials.2014.10.053
Dendritic cells (DC) play a prominent role in the priming of CD8(+) T cells. Vaccination is a promising treatment to boost tumor-specific CD8(+) T cells which is crucially dependent on adequate delivery of the vaccine to DC. Upon subcutaneous (s.c.)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cc32f55126f6bb4277ef0e5244da92d
https://hdl.handle.net/1887/3198544
https://hdl.handle.net/1887/3198544
Autor:
Dinja Oosterhoff, Jan de Groot, Victor W. van Beusechem, Joke M. M. den Haan, Rik J. Scheper, David T. Curiel, Basav N. Hangalapura, Tanja D. de Gruijl, Pepijn G.J.T.B. Wijnands, Tarun Gupta, Thomas Tüting, Alfons J.M. van den Eertwegh
Publikováno v:
Vaccine, 29, 2313-21
Vaccine
Vaccine, 29(12), 2313-2321. Elsevier BV
Vaccine, 29, 12, pp. 2313-21
Hangalapura, B N, Oosterhoff, D, Gupta, T, de Groot, J, Wijnands, P G J T B, van Beusechem, V W, den Haan, J, Tuting, T, van den Eertwegh, A J M, Curiel, D T, Scheper, R J & de Gruijl, T D 2011, ' Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine. ', Vaccine, vol. 29, no. 12, pp. 2313-2321 . https://doi.org/10.1016/j.vaccine.2011.01.022
Vaccine
Vaccine, 29(12), 2313-2321. Elsevier BV
Vaccine, 29, 12, pp. 2313-21
Hangalapura, B N, Oosterhoff, D, Gupta, T, de Groot, J, Wijnands, P G J T B, van Beusechem, V W, den Haan, J, Tuting, T, van den Eertwegh, A J M, Curiel, D T, Scheper, R J & de Gruijl, T D 2011, ' Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine. ', Vaccine, vol. 29, no. 12, pp. 2313-2321 . https://doi.org/10.1016/j.vaccine.2011.01.022
Item does not contain fulltext Adenovirus (Ad)-based vaccines are considered for cancer immunotherapy, yet, detailed knowledge on their mechanism of action and optimal delivery route for anti-tumor efficacy is lacking. Here, we compared the anti-tumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad5af5ba72d05fd55ca6e8df1cb3a835
http://hdl.handle.net/2066/96790
http://hdl.handle.net/2066/96790
Autor:
Basav N. Hangalapura, Hans J. van der Vliet, Rik J. Scheper, Sinéad M. Lougheed, Tanja D. de Gruijl, Jan de Groot, Alfons J.M. van den Eertwegh, Hetty J. Bontkes, María Moreno, B. Mary E. von Blomberg, Jelle J. Lindenberg
Publikováno v:
Clinical Immunology, 136(3), 364-374. Academic Press Inc.
Clinical Immunology, 136, 3, pp. 364-74
Bontkes, H J, Moreno Jauge, M, Hangalapura, B N, Lindenberg, J J, de Groot, J, Lougheed, S M, van der Vliet, J J, van den Eertwegh, A J M, de Gruijl, T D, von Blomberg, B M E & Scheper, R J 2010, ' Attenuation of invariant Natural Killer T-cell anergy induction through intradermal delivery of alpha-galactosylceramide ', Clinical Immunology, vol. 136, no. 3, pp. 364-374 . https://doi.org/10.1016/j.clim.2010.04.019
Clinical Immunology, 136, 364-74
Clinical Immunology, 136, 3, pp. 364-74
Bontkes, H J, Moreno Jauge, M, Hangalapura, B N, Lindenberg, J J, de Groot, J, Lougheed, S M, van der Vliet, J J, van den Eertwegh, A J M, de Gruijl, T D, von Blomberg, B M E & Scheper, R J 2010, ' Attenuation of invariant Natural Killer T-cell anergy induction through intradermal delivery of alpha-galactosylceramide ', Clinical Immunology, vol. 136, no. 3, pp. 364-374 . https://doi.org/10.1016/j.clim.2010.04.019
Clinical Immunology, 136, 364-74
Item does not contain fulltext CD1d restricted, alpha-galactosylceramide (alphaGC) responsive invariant (i)NKT cells positively regulate immune responses. Both intravenous and intradermal administered alphaGC are known to activate iNKT cells. iNKT ce